← Back to all trials
Not Yet Recruiting
NCT05714514
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
Conditions: Kidney Transplantation in Highly Sensitized Patients
Sex: All
Enrollment: 64
Sponsor: Hansa Biopharma AB
Location: United States
Summary
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Eligibility Criteria
Inclusion Criteria:Signed Informed Consent obtained before any trial-related procedures.Previous participation in the clinical trial ConfIdeS.Exclusion Criteria:1. Inability by the judgement of the investigator to participate in the trial for any reason.
Source: ClinicalTrials.gov (NCT05714514). StuddyBuddy aggregates publicly available trial information.
